AEterna Zentaris Inc. (AEZ) - Financial and Strategic SWOT Analysis Review

GlobalData, September 2011, Pages: 45

AEterna Zentaris Inc. (AEZ) - Financial and Strategic SWOT Analysis Review

Summary

AEterna Zentaris Inc. (AEterna Zentaris) is a drug development company engaged in the development of therapeutics for the treatment of principally late-stage cancer, endocrine disorders and infectious diseases. Its key product is Cetrotide, the first luteinizing hormone-releasing hormone (LHRH) antagonist and is the only marketed product of the company. AEZS-115, AEZS-112, and AEZS-108 are some pipeline products of the company. The company principally operates its operation in US, Europe And Japan. The company carries out its operations in Canada, the US and Europe. It is headquartered in Quebec, Canada.

AEterna Zentaris Inc. Key Recent Developments

Aug 23, 2011 Aeterna Zentaris To Present Poster On Oral Anticancer Erk Inhibitors At Upcoming American Chemical Society’s National Meeting
Aug 10, 2011 Aeterna Zentaris Reports Total Revenue Of $6.5m In Q2 2011
May 18, 2011 Aeterna Zentaris Reports Net Loss Of $10.1m For Q1 2011
Mar 24, 2011 Aeterna Zentaris Receives Grant From German Government To Develop New Targeted Anti-Cancer Compounds
Mar 22, 2011 Aeterna Zentaris Appoints Michael Meyers To Board

This comprehensive SWOT profile of AEterna Zentaris Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

List of Tables
List of Figures
Section 1 - About the Company
AEterna Zentaris Inc. - Key Facts
AEterna Zentaris Inc. - Key Employees
AEterna Zentaris Inc. - Key Employee Biographies
AEterna Zentaris Inc. - Major Products and Services
AEterna Zentaris Inc. - Pharmaceutical Pipeline Products Data
AEterna Zentaris Inc., Pipeline Products by Therapy Area
AEterna Zentaris Inc., Pipeline Products by Development Phase
AEterna Zentaris Inc. - Medical Equipment Pipeline Products Data
AEterna Zentaris Inc. Pipeline Products by Equipment Type
AEterna Zentaris Inc. Pipeline Products by Development Stage
AEterna Zentaris Inc. - History
AEterna Zentaris Inc. - Company Statement
AEterna Zentaris Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
AEterna Zentaris Inc. - Business Description
AEterna Zentaris Inc. - SWOT Analysis
SWOT Analysis - Overview
AEterna Zentaris Inc. - Strengths
Strength - Lead Marketed Product - Cetrorelix
Strength - Focused Research and Development
Strength - Strong Product Pipeline
Weakness - History of Operating Losses
Weakness - Dependence on Third Parties
Opportunity - Acquisition of AEZS-130
Opportunity - Collaborations and Agreements
Opportunity - Growing Oncology Market
Opportunity - Increasing Market for Multiple Myeloma
Threat - Increasing Competition
Threat - Increased Pricing Control
Threat - Stringent Government Regulations
AEterna Zentaris Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
AEterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
AEterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
AEterna Zentaris Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 23, 2011: Aeterna Zentaris To Present Poster On Oral Anticancer Erk Inhibitors At Upcoming American Chemical Society’s National Meeting
Aug 10, 2011: Aeterna Zentaris Reports Total Revenue Of $6.5m In Q2 2011
May 18, 2011: Aeterna Zentaris Reports Net Loss Of $10.1m For Q1 2011
Mar 24, 2011: Aeterna Zentaris Receives Grant From German Government To Develop New Targeted Anti-Cancer Compounds
Mar 22, 2011: Aeterna Zentaris Appoints Michael Meyers To Board
Mar 22, 2011: Aeterna Zentaris Reports Net Loss Of $2.7m For Q4 2010
Mar 15, 2011: Aeterna Zentaris To Make Oral Presentation On Targeted Inhibitors For PI3K And Erk At Cancer Conference In Berlin
Feb 22, 2011: Aeterna Zentaris To Present On New Anticancer Compounds At Upcoming Bio Partnering North America
Nov 17, 2010: Aeterna Zentaris Presents Encouraging Preclinical Data On Two Orally Active Anti-Cancer Compounds At Major Conference In Germany
Nov 09, 2010: Aeterna Zentaris Reports Net Loss Of $10.1 Million For Q3 2010
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
AEterna Zentaris Inc., Key Facts
AEterna Zentaris Inc., Key Employees
AEterna Zentaris Inc., Key Employee Biographies
AEterna Zentaris Inc., Major Products and Services
AEterna Zentaris Inc., Number of Pipeline Products by Therapy Area
AEterna Zentaris Inc., Number of Pipeline Products by Development Stage
AEterna Zentaris Inc., Pipeline Products By Therapy Area and Development Phase
AEterna Zentaris Inc. Number of Pipeline Products by Equipment Type
AEterna Zentaris Inc. Pipeline Products by Equipment Type
AEterna Zentaris Inc. Number of Pipeline Products by Development Stage
AEterna Zentaris Inc. Pipeline Products by Development Stage
AEterna Zentaris Inc., History
AEterna Zentaris Inc., Subsidiaries
AEterna Zentaris Inc., Key Competitors
AEterna Zentaris Inc., Ratios based on current share price
AEterna Zentaris Inc., Annual Ratios
AEterna Zentaris Inc., Interim Ratios
AEterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
AEterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
AEterna Zentaris Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
AEterna Zentaris Inc., Pipeline Products by Therapy Area
AEterna Zentaris Inc., Pipeline Products by Development Phase
AEterna Zentaris Inc. Pipeline Products by Equipment Type
AEterna Zentaris Inc. Pipeline Products by Development Stage
AEterna Zentaris Inc., Performance Chart (2006 - 2010)
AEterna Zentaris Inc., Ratio Charts
AEterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
AEterna Zentaris Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011

GlaxoSmithKline plc
Sanofi
Merck & Co., Inc.
Novartis AG
Celgene Corporation

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• eBay - Strong Execution
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile